Graphite Bio Inc Stock News

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Stacy Ku - TD Cowen Pawan Patel - Bank of America Yigal Nochomovitz - Citi La...

SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of presbyopia in the Republic of Korea and certain countries in Southeast Asia.

New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced that company management will participate in a fireside chat and one-on-one...

SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial stage biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, May 7th, 2025, at 4:30 p.m. EDT to ...

LENZ Therapeutics' LNZ100 for presbyopia is in an advanced approval phase, targeting a $3B+ market, with potential U.S. launch in 2025. With $209.1M in cash and no debt, LENZ is expected to reach positive cash flow in 2027-2028. A base-case Fair Value estimate is $42.55, indicating a 101% potential upside; while in an optimistic scenario with international expansion, the Fair Value estimate is ...

LENZ Therapeutics, Inc.'s LNZ100 eye drop shows promising results for presbyopia, with strong phase 3 data and potential FDA approval by August 2025. LNZ100 demonstrated superior efficacy compared to AbbVie's Vuity, with a broad patient range and rapid onset of treatment effect. Survey data indicates high interest among eye care professionals, with 82% likely to prescribe LNZ100 if approved, ta...

LENZ Therapeutics, Inc. (NASDAQ:LENZ ) Q4 2024 Results Conference Call March 19, 2025 4:30 PM ET Company Participants Dan Chevallard - Chief Financial Officer Eef Schimmelpennink - President & Chief Executive Officer Shawn Olsson - Chief Commercial Officer Marc Odrich - Chief Medical Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Yennawar - Leerink Partners Joe Catanza...